10x Genomics Inc (TXG) concluded trading on Wednesday at a closing price of $9.58, with 3.84 million shares of worth about $36.82 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -56.87% during that period and on March 26, 2025 the price saw a loss of about -1.74%. Currently the company’s common shares owned by public are about 108.24M shares, out of which, 100.79M shares are available for trading.
Stock saw a price change of -6.90% in past 5 days and over the past one month there was a price change of -13.77%. Year-to-date (YTD), TXG shares are showing a performance of -33.29% which decreased to -73.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.27 but also hit the highest price of $38.49 during that period. The average intraday trading volume for 10x Genomics Inc shares is 2.72 million. The stock is currently trading -8.77% below its 20-day simple moving average (SMA20), while that difference is down -22.83% for SMA50 and it goes to -43.09% lower than SMA200.
10x Genomics Inc (NASDAQ: TXG) currently have 108.24M outstanding shares and institutions hold larger chunk of about 79.43% of that.
The stock has a current market capitalization of $1.17B and its 3Y-monthly beta is at 1.99. It has posted earnings per share of -$1.52 in the same period. It has Quick Ratio of 4.26 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TXG, volatility over the week remained 5.87% while standing at 7.11% over the month.
Analysts are in expectations that 10x Genomics Inc (TXG) stock would likely to be making an EPS of -0.29 in the current quarter, while forecast for next quarter EPS is -0.14 and it is -0.42 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.33 which is -0.25 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.2 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 1.74% while it is estimated to increase by 22.97% in next year. EPS is likely to grow at an annualized rate of 17.46% for next 5-years, compared to annual growth of -36.10% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 13, 2025 offering a Market perform rating for the stock and assigned a target price range of between $25 and $12 to it. Coverage by Leerink Partners stated 10x Genomics Inc (TXG) stock as an Outperform in their note to investors on September 03, 2024, suggesting a price target of $35 for the stock. On July 22, 2024, Jefferies Upgrade their recommendations, while on July 18, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $20. Stock get a Hold rating from Deutsche Bank on July 10, 2024.
